In a significant breakthrough, Poolbeg Pharma announced positive pre-clinical study results for their drug POLB 001, presented at the 66th American Society of Hematology (ASH) Annual Meeting. The study focused on the drug's potential to prevent Cytokine Release Syndrome (CRS), a frequently observed
A drug initially celebrated for its potential in treating a rare liver disease has come under scrutiny following alarming safety findings. Ocaliva, developed by Intercept Pharmaceuticals and now under Alfasigma's ownership, was initially viewed as a breakthrough treatment for primary biliary
The Keck School of Medicine of USC has embarked on a groundbreaking research initiative aimed at addressing age-related cognitive decline in women. This significant effort is led by Dr. Young-Kwon Hong and has been bolstered by securing a $3.4 million federal grant from the Advanced Research
Autoimmune encephalitis (AE), a condition where the body's immune system turns against the brain, affects approximately one-third of global encephalitis cases and often leads to debilitating symptoms, including seizures, cognitive impairment, and motor dysfunctions. Despite advancements in
The International Antiviral (formerly AIDS) Society-USA (IAS-USA) has unveiled comprehensive international guidelines for the treatment and prevention of HIV, coinciding with the observance of World AIDS Day on December 1, 2024. These guidelines were meticulously developed by a panel of volunteer
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease, has become a major global health concern. Characterized by hepatic steatosis and associated with at least one cardiometabolic risk factor such as type 2 diabetes mellitus (T2DM),
